GRCL — Gracell Biotechnologies Share News
0.000.00%
Last trade - 00:00- $972.69m
- $750.11m
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27
US STOCKS-Wall Street ends higher in final stretch of 2023, rate cuts in view
US STOCKS-Wall Street ends higher in final stretch of 2023, rate cuts in view
Newscasts - U.S. Day Ahead: Apple appeals after US import ban begins
US STOCKS-Wall Street gains on final stretch of 2023, rate cuts in view
U.S. STOCKS ON THE MOVE-APA, Etsy, Global Gas
Newscasts - Trading at Noon: Retail sales rise over the holiday season
U.S. STOCKS ON THE MOVE-Carnival corp, Exxon Mobil, Vince Holding
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Intel, Gracell, RayzeBio
Brief: Gracell Biotechnologies Says Will Be Required To Pay Astrazeneca Treasury Limited $33.1 Million On Termination Of Deal Under Specified Circumstances
U.S. STOCKS ON THE MOVE-Stratasys, Intel, Gracell
Gracell soars on AstraZeneca buyout deal
Deals of the day-Mergers and acquisitions
AstraZeneca to buy China's Gracell Biotechnologies in $1.2 bln deal (updated)
AstraZeneca to buy China-based Gracell Biotechnologies in $1.2 bln deal (updated)